Golimumab is usually a human monoclonal antibody administered the moment a month by subcutaneous injection. Though it's got an analogous basic safety and efficacy profile to other TNFi, golimumab is less effective than other TNFi in people who have unsuccessful various biological treatments. Mainly because RA damages joints as time https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/